Streetbeat News

MXDHF

MDxHealth SA

https://mdxhealth.com/

CEO

Michael McGarrity

Industry

Research and Development in Biotechnology

Open

0.25

Mkt cap

8.6M

Volume

300

High

0.25

P/E Ratio

-0.12

52-wk high

0.65

Low

0.25

Div yield

N/A

52-wk low

0.00

MDxHealth SA is a strong buy due to its innovative urology diagnostics portfolio, including products like ConfirmMDx, SelectMDx, and GPS. The company reported 21% YoY revenue growth in Q3 2024 and aims for positive EBITDA by 2025.

Portfolio Pulse from

December 13, 2024 | 3:30 pm

MDxHealth SA, a precision diagnostics company, will participate in the Piper Sandler 36th Annual Healthcare Conference in New York City from December 3-5, 2024. CEO Michael K. McGarrity will represent the company.

Portfolio Pulse from

November 25, 2024 | 1:45 pm

MDxHealth SA held its Q3 2024 earnings call, discussing financial results and company performance.

Portfolio Pulse from

November 08, 2024 | 12:30 pm

MDxHealth SA reported a significant increase in test volumes and raised its 2024 revenue guidance, indicating strong growth. The company has also announced a conference call to discuss these results.

Portfolio Pulse from

November 06, 2024 | 9:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.